Loading...
ROCO
4188
Market cap27mUSD
Oct 08, Last price  
13.95TWD
1D
0.00%
1Q
30.37%
Jan 2017
-54.41%
IPO
-75.64%
Name

AmCad BioMed Corp

Chart & performance

D1W1MN
ROCO:4188 chart
P/E
—
P/S
29.03
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.55%
Rev. gr., 5y
-13.80%
Revenues
30m
-42.69%
84,086,00063,941,00085,791,00061,630,00065,256,00053,105,00030,437,000
Net income
-56m
L+10.17%
-37,741,000-35,444,000-25,544,000-53,488,000-45,314,000-50,577,000-55,719,000
CFO
-47m
L-9.23%
0-50,048,000-38,968,000-34,193,000-41,599,000-51,850,000-47,062,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.

Key people

Chairman of the Board, General Manager · since 2024
Vice Chairman of the Board · since 2020
Junlin Li
Deputy General Manager-Exhibition Industry · since 2017
Josh Chen
Head of Finance · since 2025
Danica Dai
Head of Finance & Accounting · since 2025
Zhiyuan Huang
Corporate Governance Officer · since 2024
Weide Chen
Director · since 2019
Director · since 2020
Shuti Qiu
Director · since 2020
Director · since 2020
Zaibin Wang
Director · since 2023
Jinchuan Xu
Director · since 2014
Director · since 2014
Independent Director · since 2020
Xueyu Li
Independent Director · since 2023
Seyi Lin
Independent Director · since 2023
Qingtian Zhang
Independent Director · since 2017
IPO date
Dec 26, 2013
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT